http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 박헌석 ( Heon Seok Park ) (검색결과 5 건)
- 무료
- 기관 내 무료
- 유료
-
식각된 비귀금속합금과 법랑질을 복합레진계 시멘트로 접착시킨 경우의 접착인장강도에 관한 연구
박헌석,이선형,양재호,장완식,Park, Heon-Seok,Lee, Sun-Hyung,Yang, Jae-Ho,Chang, Wan-Shik 대한치과보철학회 1986 대한치과보철학회지 Vol.24 No.1
The purpose of this study was to compare the tensile bond strength of Comspan and Panavia as a luting materials between electrochemically etched Ni-Cr-Be alloy castings and acid etchea human tooth enamel. Tensile bond strength was evaluated using an Instron testing machine at a crosshead speed of 2mm/min. The following conclusions can be drawn frfm this study ; 1. The tensile bond strength of etched-metal resin-bonded specimen was $179.0{\pm}42.5kg/cm^2$ in case of Comspan and $169.6{\pm}41.4kg/cm^2$ in case of Panavia. 2. The tensile bond strength was not significantly different between Comspan, using with bonding agent, and Panavia, using without bonding agent.
-
이종 췌도 이식을 위한 Ba²+-알진산 미세피막화 췌도 형성
박헌석 ( Heon Seok Park ),함동식 ( Dong Sik Ham ),유영혜 ( Young Hye You ),신주영 ( Ju Young Shin ),김지원 ( Ji Won Kim ),조재형 ( Jae Hyoung Jo ),김온유 ( On You Kim ),강길선 ( Gil Son Khang ),윤건호 ( Kun Ho Yoon ) 한국조직공학과 재생의학회 2010 조직공학과 재생의학 Vol.7 No.5
Islet transplantation is one of the promising treatment strategies for the cure of diabetes. However, the hurdles such as shortage of human tissue, immune rejection and recurrence of autoimmunity should be overcome for successful islet transplantation. Xeno-transplantation can be a solution to shortage of human sources. Immune isolation by microencapsulation of islet with alginate polymer could escape the immune injuries. Microencapsulated xenoislet transplantation is a one of the ideal strategies to cure the diabetes. Here, we introduce microencapsulation of islets for successful xenogenic islet transplantation. We achieved optimization of encapsulating condition. First, we demonstrated viability and insulin secreting capacity of encapsulated islets in vitro. We confirmed their ability of maintaining normoglycemia and escaping immune rejection after rat or porcine islet transplantation to diabetic mouse models.
-
임동준 ( Dong Jun Lim ),조재형 ( Jae Hyoung Cho ),최윤희 ( Yoon Hee Choi ),박헌석 ( Heon Seok Park ),홍옥기 ( Oak Kee Hong ),권혁상 ( Hyuk Sang Kwon ),손호영 ( Ho Young Son ),윤건호 ( Kun Ho Yoon ) 한국조직공학과 재생의학회 2005 조직공학과 재생의학 Vol.2 No.3
Using an air-driven droplet generator, we investigated to establish an ideal condition of microencapsulation of rat islets by simple alginate-barium microcapsules and to access viability of islets in capsules. We made empty microcapsules by changing an alginate density from 1.0% to 3.0%, an alginate infusion rate from 10 to 70 mL/hr and a CO2 flow rate from 1.0 to 7.0 L/min and decided the optimal condition in making the optimal sized capsules with less than 5% fragmented microcapsules. The adequate microcapsules sized 700-800 μm were produced at an alginate density of 1.5% (P<0.05), at an alginate infusion rate of 40 mL/hr (P<0.05), and at an air flow rate of 4.0 L/min under the minimum of fragmented microcapsules. Isolated 4000 rat islets were microencapsulated according to the above condition. There was no difference of the capsule size between the islets-encapsulated microcapsules and that of empty ones (750.5±31.3 μm vs. 826.1±31.9 μm). We compared the insulin secretion of islets encapsulated by alginate-barium microcapsule with that of naked islets (control group) through the measurement of glucose-stimulated insulin secretion at 3.3 mM glucose and at 16.7 mM glucose. Insulin secretion of microencapsulated islets had no difference from that of control group at 3.3 mM glucose but was 42% lower than that of control group at 16.7 mM glucose during 45 min incubation. Here we established the optimal conditions for microencapsulation of isolated islets, which would overcome the immunorejection in allo- and xeno-islet transplantation in diabetes patients.
-
원저 : 제2형 당뇨병 동물모델에서 항 혈관내피세포 성장인자(Anti-Vascular Endothelial Growth Factor (VEGF)) 투여 시 췌장에 대한 효과
김지원 ( Ji Won Kim ),함동식 ( Dong Sik Ham ),박헌석 ( Heon Seok Park ),안유배 ( Yu Bai Ahn ),송기호 ( Ki Ho Song ),윤건호 ( Kun Ho Yoon ),유기동 ( Ki Dong Yoo ),김명준 ( Myung Jun Kim ),정인경 ( In Kyung Jeong ),고승현 ( Seung Hy 대한당뇨병학회 2009 Diabetes and Metabolism Journal Vol.33 No.3
연구배경: 대표적인 당뇨병성 합병증인 당뇨병성 신증과 망막병증은 공통적으로 혈관내피세포성장인자(Vascular endothelial growth factor, VEGF)가 합병증의 발생에 중요한 역할을 하는 것이 알려져 있으나 항 VEGF 치료가 췌도나 베타세포에 직접적으로 어떠한 영향을 주는지는 거의 알려진 바가 없다. 이에 당뇨병성 합병증 치료를 목적으로 하는 항 VEGF 치료가 췌장과 당뇨병의 경과에 미치는 영향을 관찰하고, 당뇨병이 진행되면서 나타나는 췌도 및 베타세포의 변화에 있어서 VEGF의 역할을 규명하고 치료에 응용하고자 하였다. 방법: 이에 당뇨병 동물모델인 db/db mouse에 12주간 VEGF 수용체 type 2 antagonist (ATWLPPR, 5 mg/kg)를 복강 내 투여하여 혈당의 변화와 함께 췌장의 면역염색을 통하여 베타세포 질량 및 췌도의 형태적인 변화를 관찰하고 VEGF의 췌도 내 발현 및 혈관신생 정도를 평가하였다. 결과: 12주간 항 VEGF peptide를 투여한 결과, 복강 내당부하검사 시 db/db mouse에 비해 항 VEGF 투여군에서 현저한 고혈당을 보였으며 고혈당이 심해지면서 항 VEGF 투여군에서 체중의 증가가 적었다. 췌장의 무게(db/dm vs. db/db vs. anti-VEGF group, 0.321±0.05 vs. 0.206±0.13 vs. 0.158±0.12 g) 및 베타세포 질량(db/dm vs. db/db vs. anti-VEGF group, 4.08±0.1 vs. 3.77±0.2 vs. 2.89±0.2 mg, P<0.05) 역시 db/db군에 비해 항 VEGF군에서 더 감소되었다. 또한 정상 췌도에 비해 당뇨병이 발생한 군에서 췌도 내 VEGF 발현이 증가되었으나, 항 VEGF 투여시 췌도 내 VEGF 단백의 발현이 감소하였고(db/dm vs. db/db vs. anti-VEGF group, 3.63±2.86 vs. 6.60±3.56 vs. 2.74±1.55%, * P<0.05) 췌도의 크기가 감소하였으며, 췌도 내 섬유화 진행이 더 심하게 관찰되었고(db/dm vs. db/db vs. anti-VEGF group, 3.37±1.51 vs. 13.96±3.20 vs. 16.99±4.96%, * P<0.05) 췌도 내 내피세포의 증식이 더 감소되어 있었다. 결론: 제2형 당뇨병 동물모델에서 혈관내피세포 성장인자(VEGF)는 정상 췌도보다 당뇨병이 발생한 췌도에서 발현이 증가되므로 당뇨병의 발병 기전과 관련이 있을 것이며, 베타세포의 증식 및 췌도 변형에 중요한 역할을 하므로 당뇨병의 치료에도 응용할 수 있을 것으로 생각되고, 당뇨병성 미세혈관 합병증의 치료나 예방을 목적으로 제2형 당뇨병모델에 항 VEGF를 투여할 경우 고혈당 상태를 더 악화시키고 베타세포 증식을 억제하며 췌도 파괴를 가속화 시키므로, 항 VEGF 치료 시 이에 대한 충분한 고려가 필요할 것이다. Background: Vascular endothelial growth factor (VEGF) is associated with the development of diabetic complications. However, it is unknown whether systemic VEGF treatment has any effects on the pancreatic islets in an animal model of type 2 diabetes mellitus. Methods: Anti-VEGF peptide (synthetic ATWLPPR, VEGF receptor type 2antagonist) was injected into db/db mice for 12 weeks. We analyzed pancreatic islet morphology and quantified beta-cell mass. Endothelial cell proliferation and the severity of islet fibrosis were also measured. VEGF expression in isolated islets was determined using Western blot analysis. Results: When anti-VEGF was administered, db/db mice exhibited more severe hyperglycemia and associated delayed weight gain than non-treated db/db mice. Pancreas weight and pancreatic beta-cell mass were also significantly decreased in the anti-VEGF-treated group. VEGF and VEGF receptor proteins (types 1 and 2) were expressed in the pancreatic islets, and their expression was significantly increased in the db/db group compared with the db/dm group. However, the elevated VEGF expression was significantly reduced by anti-VEGF treatment compared with the db/db group. The anti-VEGF-treated group had more prominent islet fibrosis and islet destruction than db/db mice. Intra-islet endothelial cell proliferation was also remarkably reduced by the anti-VEGF peptide. Conclusion: Inhibition of VEGF action by the VEGF receptor 2antagonist not only suppressed the proliferation of intra-islet endothelial cells but also accelerated pancreatic islet destruction and aggravated hyperglycemia in a type 2 diabetes mouse model. Therefore, the potential effects of anti-VEGF treatment on pancreatic beta cell damage should be considered. (Korean Diabetes J 33:185-197, 2009)
-
RISS
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
